MedWell Ai (OTCQB: MWAI) reported revenue of $548,315 for the fiscal second quarter ended December 31, 2025, representing an increase of more than 280% from $142,861 in the prior-year period. The company's six-month revenue reached $1,075,806, reflecting growth exceeding 700% year-over-year. These financial results indicate significant momentum in the company's operations and market penetration.
Beyond revenue growth, MedWell Ai demonstrated improved financial metrics across multiple areas. The company reported reduced operating losses, lower general and administrative expenses, and improved net loss per share for both the three- and six-month periods. Additionally, liabilities decreased to $468,655 from $805,500 as of June 30, 2025, suggesting strengthened financial positioning and more efficient capital management.
The company attributes these positive developments to progress in its AI-driven pharmaceutical, healthcare and wellness portfolio strategy. MedWell Ai operates through three primary business segments: MedWell USA, LLC, which serves as a B2B distribution and e-commerce ordering portal for pharmaceutical products; MedWell Direct, LLC DBA TeleMD.Ai, which develops and operates telemedicine platforms connecting consumers and corporations with licensed healthcare providers; and MedWell Facilities, LLC, which focuses on real estate development for health and wellness tenants alongside AI-driven software platforms for clinic optimization.
These financial results matter because they demonstrate MedWell Ai's ability to scale its operations while improving financial efficiency. The substantial revenue growth suggests market acceptance of the company's AI-driven healthcare solutions, while the reduced losses and liabilities indicate progress toward sustainable operations. For investors and industry observers, these metrics provide tangible evidence that the company's strategic focus on integrating artificial intelligence with pharmaceutical distribution, telemedicine, and healthcare facility management is yielding measurable results.
The implications of this announcement extend beyond the immediate financial figures. The company's performance suggests that its multi-pronged approach to healthcare innovation—combining traditional pharmaceutical distribution with telemedicine platforms and AI-optimized clinic management—may represent a viable model for modern healthcare delivery. As healthcare continues to evolve toward more integrated, technology-driven solutions, MedWell Ai's progress offers insights into how AI can be practically applied across different healthcare verticals to drive growth and operational efficiency.
For additional information about the company's operations, visit https://www.medwellai.com and https://www.medwellusa.com. The full press release containing these financial results is available through the company's communications channels.
